{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:39:54Z","timestamp":1794335994088,"version":"4.9.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s12350-023-03297-1","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T15:01:35Z","timestamp":1684940495000},"page":"2464-2476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: systematic review and meta-analysis"],"prefix":"10.1016","volume":"30","author":[{"given":"Nanki","family":"Ahluwalia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golnaz","family":"Roshankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Draycott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Jimenez-Zepeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowell","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghee","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s12350-023-03297-1_bib1","first-page":"322","article-title":"CCS\/CHFS joint position statement on the evaluation and management of patients with cardiac amyloidosis","volume":"36","author":"Fine","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1007\/s12350-023-03297-1_bib2","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1007\/s12350-023-03297-1_bib3","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-023-03297-1_bib4","first-page":"179","article-title":"A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"15","author":"Coelho","year":"2020","journal-title":"J Rare Dis"},{"key":"10.1007\/s12350-023-03297-1_bib5","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2\u2014evidence base and standardized methods of imaging","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1007\/s12350-023-03297-1_bib6","doi-asserted-by":"crossref","unstructured":"Sperry BW, Bateman TM, Akin EA, Bravo PE, Chen W, Dilsizian V et al. Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM. J Nucl Cardiol 2022","DOI":"10.2967\/jnumed.122.264311"},{"key":"10.1007\/s12350-023-03297-1_bib7","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1007\/s12350-023-03297-1_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1007\/s12350-023-03297-1_bib9","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jcmg.2020.08.027","article-title":"Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in evolution","volume":"14","author":"Poterucha","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-023-03297-1_bib10","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-023-03297-1_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1007\/s12350-023-03297-1_bib12","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","article-title":"How to image cardiac amyloidosis: a practical approach","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-023-03297-1_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1007\/s12350-023-03297-1_bib14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1007\/s12350-023-03297-1_bib15","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1007\/s12350-023-03297-1_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/1536867X0900900203","article-title":"Metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression","volume":"9","author":"Harbord","year":"2009","journal-title":"STATA J"},{"key":"10.1007\/s12350-023-03297-1_bib17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1007\/s12350-023-03297-1_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12350-016-0610-4","article-title":"Standardization of Technetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis","volume":"25","author":"Bokhari","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03297-1_bib19","first-page":"1221","article-title":"Diagnosing transthyretin cardiac amyloidosis by Technetium Tc 99m pyrophosphate","volume":"14","author":"Poterucha","year":"2021","journal-title":"JACC"},{"key":"10.1007\/s12350-023-03297-1_bib20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1007\/s12350-023-03297-1_bib21","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1007\/s12350-023-03297-1_bib22","doi-asserted-by":"crossref","unstructured":"Watanabe S, Nakajima K, Hiroshi W, et al. Volumetric evaluation of 99mTc-pyrophosphate SPECT\/CT for transthyretin cardiac amyloidosis: methodology and correlation with cardiac functional parameters. J Nucl Cardiol 2021","DOI":"10.1007\/s12350-021-02857-7"},{"key":"10.1007\/s12350-023-03297-1_bib23","doi-asserted-by":"crossref","unstructured":"Miller RJH, Cadet S, Mah D, Pournazari P, Chan D, Fine NM et al. Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis. J Nucl Cardiol 2021.","DOI":"10.1007\/s12350-021-02563-4"},{"key":"10.1007\/s12350-023-03297-1_bib24","doi-asserted-by":"crossref","unstructured":"Roshankar G, White GC, Cadet S, Fine NM, Chan D, White JA et al. Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis. J Nucl Cardiol 2021.","DOI":"10.1016\/S0735-1097(21)02708-X"},{"key":"10.1007\/s12350-023-03297-1_bib25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2967\/jnumed.120.247312","article-title":"Absolute quantitation of cardiac (99m)Tc-pyrophosphate using cadmium-zinc-telluride-based SPECT\/CT","volume":"62","author":"Dorbala","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-023-03297-1_bib26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13550-021-00828-0","article-title":"Quantitative SPECT\/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis","volume":"11","author":"Ben-Haim","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1007\/s12350-023-03297-1_bib27","doi-asserted-by":"crossref","unstructured":"Ren C, Ren J, Tian Z, Du Y, Hao Z, Zhang Z et al. Assessment of cardiac amyloidosis with (99m)Tc-pyrophosphate (PYP) quantitative SPECT. EJNMMI Phys 2021;8:3","DOI":"10.1186\/s40658-020-00342-7"},{"key":"10.1007\/s12350-023-03297-1_bib28","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jcmg.2020.03.020","article-title":"DPD quantification in cardiac amyloidosis","volume":"13","author":"Scully","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-023-03297-1_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41824-018-0035-1","article-title":"Tc-HDP quantitative SPECT\/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population","volume":"2","author":"Ramsay","year":"2018","journal-title":"Eur J Hybrid Imaging"},{"key":"10.1007\/s12350-023-03297-1_bib30","doi-asserted-by":"crossref","unstructured":"Miller RJH, Fine N. Quantifying is believing: techniques for evaluating transthyretin cardiac amyloidosis burden for expanded clinical applications. J Nucl Cardiol 2021","DOI":"10.1007\/s12350-021-02880-8"},{"key":"10.1007\/s12350-023-03297-1_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-023-03297-1_bib32","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00259-010-1642-7","article-title":"Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy","volume":"38","author":"Rapezzi","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1007\/s12350-023-03297-1_bib33","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.recesp.2011.12.015","article-title":"Role of cardiac scintigraphy with 99mTc-DPD in the differentiation of cardiac amyloidosis subtype","volume":"65","author":"de Haro-del Moral","year":"2012","journal-title":"Rev Esp Cardiol"},{"key":"10.1007\/s12350-023-03297-1_bib34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1007\/s12350-023-03297-1_bib35","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/ehjci\/jeu107","article-title":"Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis","volume":"15","author":"Hutt","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1007\/s12350-023-03297-1_bib36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/13506129.2015.1072089","article-title":"Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis","volume":"22","author":"Galat","year":"2015","journal-title":"Amyloid"},{"key":"10.1007\/s12350-023-03297-1_bib37","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.hlc.2016.12.017","article-title":"The utility of (99m)Tc-DPD scintigraphy in the diagnosis of cardiac amyloidosis","volume":"26","author":"Moore","year":"2017","journal-title":"Heart Lung Circ"},{"key":"10.1007\/s12350-023-03297-1_bib38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s12350-017-0922-z","article-title":"Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis","volume":"26","author":"Cappelli","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03297-1_bib39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12350-019-01643-w","article-title":"Semi-quantitative indices of cardiac uptake in patients with suspected cardiac amyloidosis undergoing 99mTc-HMDP scintigraphy","volume":"28","author":"Gallini","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03297-1_bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12350-019-01831-8","article-title":"99mTechnetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis","volume":"27","author":"Flaherty","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03297-1_bib41","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.010249","article-title":"Efficient 1-hour Technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis","volume":"13","author":"Masri","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1007\/s12350-023-03297-1_bib42","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s12350-020-02139-8","article-title":"Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 hours and planar vs SPECT\/CT","volume":"27","author":"Sperry","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03297-1_bib43","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12350-019-01753-5","article-title":"Simultaneous Tc-99m PYP\/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis","volume":"27","author":"Tamarappoo","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03297-1_bib44","doi-asserted-by":"crossref","unstructured":"Ikoma T, Ohtani H, Ohno K, Iguchi K, Suwa K, Sawada M et al. Diagnostic value of heart-to-mediastinum ratio in (99m)Tc-pyrophospate SPECT\/CT for transthyretin cardiac amyloidosis. J Nucl Cardiol 2022","DOI":"10.1007\/s12350-022-03180-5"},{"key":"10.1007\/s12350-023-03297-1_bib45","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12350-022-02960-3","article-title":"Quantitative (99m)Tc-DPD-SPECT\/CT assessment of cardiac amyloidosis","volume":"30","author":"Kessler","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03297-1_bib46","doi-asserted-by":"crossref","unstructured":"Matsuda N, Otsuka H, Otani T, Azane S, Kunikane Y, Otomi Y et al. New quantitative indices of cardiac amyloidosis with 99mTc-pyrophosphate scintigraphy. Japanese J Radiol 2022","DOI":"10.1007\/s11604-022-01364-0"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-023-03297-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12350-023-03297-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358124001880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358124001880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-023-03297-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:13:46Z","timestamp":1761027226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358124001880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1071358124001880"],"URL":"https:\/\/doi.org\/10.1007\/s12350-023-03297-1","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12350-023-03297-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}